IL-6 levels and disease characteristics (n = 151)
| Category . | No. patients . | Median IL-6 (pg/mL) (range) . | P value* . |
|---|---|---|---|
| β2-microglobulin (mg/L)1 | |||
| <2 | 24 | <0.91 (<0.91-11) | <.001 |
| ≥2 | 104 | 1.93 (<0.91-110) | |
| Previous treatment | |||
| Yes | 89 | 2.16 (<0.91-110) | .0004 |
| No | 62 | <0.91 (<0.91-37) | |
| Serum LDH level (IU/mL)† | |||
| ≥618 | 24 | 2.91 (<0.91-74) | .02 |
| <618 | 112 | 1.20 (<0.91-110) | |
| Rai stage | |||
| 0, I, II | 124 | 1.04 (<0.91-110) | .0001 |
| III, IV | 27 | 2.94 (<0.91-51) | |
| Age (y) | |||
| <60 | 77 | <0.091 (<0.91-80) | .003 |
| ≥60 | 74 | 2.01 (<0.91-110) |
| Category . | No. patients . | Median IL-6 (pg/mL) (range) . | P value* . |
|---|---|---|---|
| β2-microglobulin (mg/L)1 | |||
| <2 | 24 | <0.91 (<0.91-11) | <.001 |
| ≥2 | 104 | 1.93 (<0.91-110) | |
| Previous treatment | |||
| Yes | 89 | 2.16 (<0.91-110) | .0004 |
| No | 62 | <0.91 (<0.91-37) | |
| Serum LDH level (IU/mL)† | |||
| ≥618 | 24 | 2.91 (<0.91-74) | .02 |
| <618 | 112 | 1.20 (<0.91-110) | |
| Rai stage | |||
| 0, I, II | 124 | 1.04 (<0.91-110) | .0001 |
| III, IV | 27 | 2.94 (<0.91-51) | |
| Age (y) | |||
| <60 | 77 | <0.091 (<0.91-80) | .003 |
| ≥60 | 74 | 2.01 (<0.91-110) |